Biopharma Core Services
Precision Medicine Starts with Molecular Profiling
The fundamental understanding of disease at the molecular level is the essence of precision medicine. With whole exome and whole transcriptome sequencing, plus protein analysis and whole slide imaging, Caris has built the molecular profiling platforms and data solutions to unravel the molecular complexities of disease and is uniquely positioned help bring novel therapies and interventions to market faster – and with fewer costs.
- Tissue & Blood Profiling
- Clinical Trial Matching
- Customized IHC Validation
- Sales Force Targeting
- CDx & Commercialization Services
DOCUMENT DOWNLOADS
Caris Biopharma Brochure
Biopharma Dealmakers Article
Biopharma Data Overview
Built upon industry-leading, comprehensive molecular profiling that includes whole exome and whole transcriptome sequencing in both tissue and blood, Caris provides actionable insights to inform your precision medicine programs.
Molecular Profiling
Unlock Actionable Insights
The Caris molecular profiling approach is widely recognized as the most comprehensive and clinically relevant tumor profiling portfolio on the market. For tissue-based profiling, Caris analyzes DNA and RNA (23,000+ gene coverage via WES and WTS), plus proteins, as well as leverages proprietary molecular AI-based signatures across all solid tumors. For blood-based profiling, Caris performs WES and WTS for pathogenic and likely pathogenic tumor-derived, incidental germline, and incidental CH variant detection.
Analyze 23,000 genes through whole exome (WES-DNA), whole transcriptome sequencing (WTS-RNA), plus Immunohistochemistry (IHC-proteins) and H&E slides.
Clinical Trials Powered by Data
Caris’ patient-matched molecular and clinical data can help find the answers to the most challenging clinical development questions. With massive, integrated data covering single gene biomarkers, complex genome-wide signatures, fusions, IHC and H&E slide data, Caris enables biopharma partners to gain insights into patient cohorts and clinical outcomes throughout the patient journey, providing multiple pathways for success.
Innovative Commercialization Resources for Biopharma
- Tissue agnostic CDx and tumor profiling claims support use for solid tumor indications
- Feasibility and development, analytical, and clinical validation solutions
- Strong global clinical and regulatory support in U.S. and ex-U.S. IVD markets
Discover
More
Caris Life Sciences is at the forefront of a data-led revolution in personalized cancer care. In partnership with biopharma innovators, Caris is shaping the future of precision oncology by developing groundbreaking solutions that deliver powerful outcomes.
Despite transformational breakthroughs in our understanding of disease, drug development has focused on a redundant, limited number of targets.
Get Answers from Caris Biopharma
"*" indicates required fields